Peripheral Neuropathy Market

Global Peripheral Neuropathy Market by Types (Idiopathic Peripheral Neuropathy, HIV/AIDS Associated Peripheral Neuropathy, Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, and Others), Treatments (Pharmacological Therapies [Pain Relievers, Anti-seizure Medications and Antidepressants] and Non-pharmacological Therapies [Transcutaneous Electrical Nerve Stimulation, Plasma Exchange & Intravenous Immune Globulin, and Others]), End-users (Ambulatory Centres, Clinics, Hospitals, and Others), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) Forecasts, 2021-2028

  • Report ID: HC-2952
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 188
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global peripheral neuropathy market is anticipated to register a substantial CAGR during the forecast period, between 2021 and 2028. The peripheral nervous system connects nerves from the brain to the rest of a live organism's body. Hands, arms, feet, legs, internal organs, face, and mouth are all connected to the brain through peripheral nerves. Damage to the nerves outside the brain and peripheral nerves causes discomfort and numbness, as well as weakness in feet and hands. Diabetes, alcohol consumption, genetic disease, dietary deficiencies, chronic kidney illness, and elderly population are all causes of peripheral neuropathy. Burning pain, changes in blood pressure, muscle weakness, cardiac intolerance and onset of numbness, are all possible symptoms of peripheral neuropathy. It can also have an impact on other parts of your body. As well as peripheral neuropathy if left untreated, can result in catastrophic consequences such as scorching paralysis or agony.


Peripheral Neuropathy Market_Key Takeaways

Market Trends, Drivers, Restraints, and Opportunities:

  • Growing prevalence of diabetes and increasing elderly population are estimated to drive market expansion during the forecast period.
  • Rising mergers and acquisitions by leading peripheral neuropathy market players can enhance the market in the future.
  • Increased chemotherapy treatments for cancer and technological advancements can benefit the market growth.
  • Government rules and adverse effects of the medications are projected to hinder the market growth.
  • Growing awareness about peripheral neuropathy is anticipated to boost the market expansion.

Scope of the report:

The report on the peripheral neuropathy market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Attributes

Details

Report Title

Peripheral Neuropathy Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018 & 2019

Forecast Period

2021–2028

Segmentation

Types (Idiopathic Peripheral Neuropathy, HIV/AIDS Associated Peripheral Neuropathy, Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, and Others), Treatments (Pharmacological Therapies [Pain Relievers, Anti-seizure Medications and Antidepressants] and Non-pharmacological Therapies [Transcutaneous Electrical Nerve Stimulation, Plasma Exchange & Intravenous Immune Globulin, and Others]), End-users (Ambulatory Centres, Clinics, Hospitals, and Others)

Regional Scope

Asia Pacific, North America, Europe, Latin America, and Middle East & Africa

Report Coverage

Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast

Key Players Covered in the Report

Bristol Myers Squibb, Reddy's Laboratories, Abbott Laboratories, Eli Lilly and Company, Novartis AG, Merck and Co. Inc., GlaxoSmithKline plc, Cipla Limited, Pfizer Inc, Hoffmann-La Roche Ltd., Lupin Limited, and RxFunction, Inc

Peripheral Neuropathy Market Segment Insights:

Diabetic peripheral neuropathy segment is projected to hold significant market share

Based on types, the peripheral neuropathy market can be segmented into idiopathic peripheral neuropathy, HIV/AIDS associated peripheral neuropathy, diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, and others. The diabetic peripheral neuropathy segment is projected to hold a significant market share. The increase in the prevalence of diabetic patients around the world has increased the desire for therapies that are safe and effective with fewer risks when compared to invasive techniques, which is driving the segment expansion.


Peripheral Neuropathy Market By Types

Pharmacological therapies segment is anticipated to account for a substantial share

On the basis of types, the market can be bifurcated into pharmacological therapies and non-pharmacological therapies. The pharmacological therapies can be further fragmented into pain relievers, anti-seizure medications, and antidepressants. The non-pharmacological therapies segment can be segmented into transcutaneous electrical nerve stimulation, plasma exchange & intravenous immune globulin, and others. The pharmacological therapies segment is anticipated to account for a substantial share due to rising prevalence of diabetes, which demands long-term medicine. The use of non-pharmacologic treatments to manage neuropathic pain is constantly increasing, which is estimated to drive the non-pharmacological therapies segment.

Hospitals segment is anticipated to expand at a rapid pace during the forecast period

In terms of end-users, the peripheral neuropathy market can be segregated into ambulatory centres, clinics, hospitals, and others. The hospitals segment is anticipated to expand at a rapid pace during the forecast period. The increased number of diabetes patients visiting hospitals for routine examinations, monitoring of health problems, and other reasons have increase demand for hospitals. Increased government support for diabetic health management by supplying effective pharmaceuticals in hospitals is also promoting the development of hospitals, resulting in the segment growth.

North America is expected to dominate the market

In terms of regions, the market is classified as Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to dominate the market owing to availability of innovative treatments and compounded drugs. The rising number of cancer cases in Europe and increased awareness of peripheral neuropathy treatment options are projected to drive the expansion of the European peripheral neuropathy market.


Peripheral Neuropathy Market By Regions

Segments

Segments Covered in the Report:
By Types
  • Idiopathic Peripheral Neuropathy
  • HIV/AIDS Associated Peripheral Neuropathy
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Others
By Treatments
  • Pharmacological Therapies
    • Pain Relievers
    • Anti-seizure Medications
    • Antidepressants
  • Non-pharmacological Therapies
    • Transcutaneous Electrical Nerve Stimulation
    • Plasma Exchange & Intravenous Immune Globulin
    • Others
By End-users
  • Ambulatory Centres
  • Clinics
  • Hospitals
  • Others
By Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
By Key Players
  • Bristol Myers Squibb
  • Reddy's Laboratories
  • Abbott Laboratories
  • Eli Lilly and Company
  • Novartis AG
  • Merck and Co. Inc
  • GlaxoSmithKline plc
  • Cipla Limited
  • Pfizer Inc
  • Hoffmann-La Roche Ltd
  • Lupin Limited
  • RxFunction, Inc

Competitive Landscape

Key players in the peripheral neuropathy market are Bristol Myers Squibb, Reddy's Laboratories, Abbott Laboratories, Eli Lilly and Company, Novartis AG, Merck and Co. Inc., GlaxoSmithKline plc, Cipla Limited, Pfizer Inc, Hoffmann-La Roche Ltd., Lupin Limited, and RxFunction, Inc. These players have widely engaged in several market development activities including collaborations, agreements, mergers & acquisitions, production capacity expansion, new product launches, and partnerships to strengthen their geographical presence and expand their customer base globally.

Peripheral Neuropathy Market By Key Players
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Peripheral Neuropathy Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Peripheral Neuropathy Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Peripheral Neuropathy Market - Supply Chain
  4.5. Global Peripheral Neuropathy Market Forecast
     4.5.1. Peripheral Neuropathy Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Peripheral Neuropathy Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Peripheral Neuropathy Market Absolute $ Opportunity
5. Global Peripheral Neuropathy Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Peripheral Neuropathy Market Size and Volume Forecast by Types
     5.3.1. Idiopathic Peripheral Neuropathy HIV/AIDS Associated Peripheral Neuropathy Diabetic Peripheral Neuropathy Chemotherapy-induced Peripheral Neuropathy Others
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Peripheral Neuropathy Market Analysis and Forecast by End Users
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by End Users
     6.2.2. Y-o-Y Growth Projections by End Users
  6.3. Peripheral Neuropathy Market Size and Volume Forecast by End Users
     6.3.1. Ambulatory Centres Clinics Hospitals Others
  6.4. Absolute $ Opportunity Assessment by End Users
  6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Peripheral Neuropathy Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Peripheral Neuropathy Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Peripheral Neuropathy Demand Share Forecast, 2019-2026
8. North America Peripheral Neuropathy Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Peripheral Neuropathy Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Peripheral Neuropathy Market Size and Volume Forecast by Types
     8.4.1. Idiopathic Peripheral Neuropathy HIV/AIDS Associated Peripheral Neuropathy Diabetic Peripheral Neuropathy Chemotherapy-induced Peripheral Neuropathy Others
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Peripheral Neuropathy Market Size and Volume Forecast by End Users
     8.7.1. Ambulatory Centres Clinics Hospitals Others
  8.8. Basis Point Share (BPS) Analysis by End Users
  8.9. Y-o-Y Growth Projections by End Users
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Peripheral Neuropathy Demand Share Forecast, 2019-2026
9. Latin America Peripheral Neuropathy Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Peripheral Neuropathy Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Peripheral Neuropathy Market Size and Volume Forecast by Types
     9.4.1. Idiopathic Peripheral Neuropathy HIV/AIDS Associated Peripheral Neuropathy Diabetic Peripheral Neuropathy Chemotherapy-induced Peripheral Neuropathy Others
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Peripheral Neuropathy Market Size and Volume Forecast by End Users
     9.7.1. Ambulatory Centres Clinics Hospitals Others
  9.8. Basis Point Share (BPS) Analysis by End Users
  9.9. Y-o-Y Growth Projections by End Users
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Peripheral Neuropathy Demand Share Forecast, 2019-2026
10. Europe Peripheral Neuropathy Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Peripheral Neuropathy Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Peripheral Neuropathy Market Size and Volume Forecast by Types
     10.4.1. Idiopathic Peripheral Neuropathy HIV/AIDS Associated Peripheral Neuropathy Diabetic Peripheral Neuropathy Chemotherapy-induced Peripheral Neuropathy Others
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Peripheral Neuropathy Market Size and Volume Forecast by End Users
     10.7.1. Ambulatory Centres Clinics Hospitals Others
  10.8. Basis Point Share (BPS) Analysis by End Users
  10.9. Y-o-Y Growth Projections by End Users
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Peripheral Neuropathy Demand Share Forecast, 2019-2026
11. Asia Pacific Peripheral Neuropathy Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Peripheral Neuropathy Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Peripheral Neuropathy Market Size and Volume Forecast by Types
     11.4.1. Idiopathic Peripheral Neuropathy HIV/AIDS Associated Peripheral Neuropathy Diabetic Peripheral Neuropathy Chemotherapy-induced Peripheral Neuropathy Others
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Peripheral Neuropathy Market Size and Volume Forecast by End Users
     11.7.1. Ambulatory Centres Clinics Hospitals Others
  11.8. Basis Point Share (BPS) Analysis by End Users
  11.9. Y-o-Y Growth Projections by End Users
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Peripheral Neuropathy Demand Share Forecast, 2019-2026
12. Middle East & Africa Peripheral Neuropathy Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Peripheral Neuropathy Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Peripheral Neuropathy Market Size and Volume Forecast by Types
     12.4.1. Idiopathic Peripheral Neuropathy HIV/AIDS Associated Peripheral Neuropathy Diabetic Peripheral Neuropathy Chemotherapy-induced Peripheral Neuropathy Others
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Peripheral Neuropathy Market Size and Volume Forecast by End Users
     12.7.1. Ambulatory Centres Clinics Hospitals Others
  12.8. Basis Point Share (BPS) Analysis by End Users
  12.9. Y-o-Y Growth Projections by End Users
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Peripheral Neuropathy Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Peripheral Neuropathy Market: Market Share Analysis
  13.2. Peripheral Neuropathy Distributors and Customers
  13.3. Peripheral Neuropathy Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Bristol Myers Squibb Reddy's Laboratories Abbott Laboratories Eli Lilly and Company Novartis AG Merck and Co. Inc  
Segments Covered in the Report:
By Types
  • Idiopathic Peripheral Neuropathy
  • HIV/AIDS Associated Peripheral Neuropathy
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-induced Peripheral Neuropathy
  • Others
By Treatments
  • Pharmacological Therapies
    • Pain Relievers
    • Anti-seizure Medications
    • Antidepressants
  • Non-pharmacological Therapies
    • Transcutaneous Electrical Nerve Stimulation
    • Plasma Exchange & Intravenous Immune Globulin
    • Others
By End-users
  • Ambulatory Centres
  • Clinics
  • Hospitals
  • Others
By Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
By Key Players
  • Bristol Myers Squibb
  • Reddy's Laboratories
  • Abbott Laboratories
  • Eli Lilly and Company
  • Novartis AG
  • Merck and Co. Inc
  • GlaxoSmithKline plc
  • Cipla Limited
  • Pfizer Inc
  • Hoffmann-La Roche Ltd
  • Lupin Limited
  • RxFunction, Inc

Key players in the peripheral neuropathy market are Bristol Myers Squibb, Reddy's Laboratories, Abbott Laboratories, Eli Lilly and Company, Novartis AG, Merck and Co. Inc., GlaxoSmithKline plc, Cipla Limited, Pfizer Inc, Hoffmann-La Roche Ltd., Lupin Limited, and RxFunction, Inc. These players have widely engaged in several market development activities including collaborations, agreements, mergers & acquisitions, production capacity expansion, new product launches, and partnerships to strengthen their geographical presence and expand their customer base globally.

Peripheral Neuropathy Market By Key Players

Buy Report